CAR T-cell therapy has emerged as a promising therapy for relapsed and/or refractory patients with multiple myeloma. Ananda Plate, LL.B, MSc, Myeloma Patients Europe, Brussels, Belgium, discusses the challenges associated with this therapy from a patients’ perspective. The time lag between the collection and manufacturing of CAR T-cells remains difficult for patients with progressive disease. Side-effects, access to CAR T-cells, and management of expectations are some of the other hurdles related to CAR T-cell therapy. This interview took place during the 3rd European CAR T-cell Meeting.

свернуть